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ABSTRACT
Background and Objectives: Beta-blockers are indicated in patients with heart failure (HF) 
with reduced ejection fraction. However, their efficacy in patients with HF with preserved 
ejection fraction (HFpEF) is uncertain. We investigated the hypothesis that beta-blockers are 
associated with reduced adverse events in patients with HFpEF.
Methods: The Korea Acute Heart Failure (KorAHF) is a prospective observational multicentre 
cohort study. The 5,625 patients hospitalized for acute HF syndrome in 10 tertiary university 
hospitals across the country have been consecutively enrolled between March 2011 and 
February 2014. Of these patients, 2,152 patients with HFpEF (ejection fraction ≥40%) were 
investigated. The primary outcome was all-cause mortality according to beta-blocker use.
Results: During a median follow-up duration of 807 days, 702 patients died. In Cox 
proportional hazards model beta-blocker use was associated with a 14% reduced all-cause 
death (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.75–0.98), but not with reduce 
rehospitalization (HR, 1.03; 95% CI, 0.85–1.27). In the propensity-score matched population, 
beta-blockers were also associated with reduced all-cause death (HR, 0.80; 95% CI, 0.69–0.94) 
but not with reduced rehospitalization (HR, 1.08; 95% CI, 0.87–1.33).
Conclusions: In Korean patients with HFpEF, use of beta-blockers is associated with reduced 
all-cause death but not with reduced rehospitalization.
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INTRODUCTION
The diagnosis of heart failure with preserved ejection fraction (HFpEF) is more difficult 
than that of heart failure with reduced ejection fraction (HFrEF) because it is not based upon 
objective parameter, i.e., ejection fraction (EF), but excluding other potential causes of 
symptom suggestive of heart failure (HF). The prevalence of HFpEF is increasing relative to 
HFrEF.1) Previous data suggested that HFpEF is a separate syndrome from HFrEF regarding 
to pathophysiology, neuroendocrine activation, aetiology, co-morbidities, and treatment 
response.2-4) Numerous drugs and device therapy have improved outcomes in patients with 
HFrEF, but there is no specific treatment option for HFpEF yet.5) Several drugs, already proven 
to be effective in HFrEF, have all failed to reduce mortality in patients with HFpEF.6-8) These 
results convincingly indicate that treatments that are effective in patients HFrEF cannot 
be directly applied to patients with HFpEF. The trials for beta-blocker have also reported 
controversial results in HFpEF. In Japanese Diastolic Heart Failure (J-DHF) trial, carvedilol did 
not improve a composite of cardiovascular death and unplanned hospitalization in HFpEF.9) On 
the other hands, a meta-analysis including observational studies showed a significant survival 
benefit of the use of beta-blocker for all-cause mortality, but not for HF hospitalization.10)
Recently, Lund et al.11) demonstrated that use of beta-blockers was associated with lower 
all-cause mortality but not with combined all-cause mortality or HF hospitalization. HF 
registries have raised the issue of heterogeneity, including geographic and ethnic variations. 
Thus, registries in different regions of the world can facilitate better understanding of HF.
The Korea Acute Heart Failure (KorAHF) registry is a prospective multicentre cohort.12) From 
the KorAHF registry, we investigated the hypothesis that beta-blockers are associated with 
reduced adverse events in patients with HFpEF.
METHODS
Study population and data collection
The KorAHF registry has been previously described.12) Briefly, 5,625 patients hospitalized for 
acute heart failure syndrome from 10 tertiary university hospitals throughout the country have 
been consecutively enrolled since March 2011 to February 2014. Detailed information on the 
study design and its results have been previously reported (ClinicalTrial.gov, NCT01389843).13) 
Patients who have signs or symptoms of HF and one of the following criteria are eligible for 
the study; lung congestion or objective findings of left ventricular (LV) systolic dysfunction 
or structural heart disease. The study protocol was approved by the Ethics Committee/
Institutional Review Board at each hospital. Written informed consent was waived by the Ethics 
Committee/Institutional Review Board. The study complied with the Declaration of Helsinki.
Study variables and definitions
HFpEF was defined as left ventricular ejection fraction (LVEF) ≥40%. Considering the 
controversy of cut-off value of ejection fraction, the sensitivity analysis using another cut-
off value (≥50%) was performed.14) Beta-blocker dose at baseline was standardized with 
carvedilol equivalents and analyzed as discrete dose groups (0, 1 to 13, 14 to 25, 26 to 50, and 
51 to 200 mg daily). The following doses are equivalent to carvedilol 25 mg; acebutolol 200 
mg, metoprolol 100 mg, propranolol 80 mg, atenolol 50 mg, bisoprolol 5 mg, nadolol 80 mg, 
and labetolol 200 mg. Dosing groups were selected on the basis of the common titration 
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schedule for carvedilol (i.e., doubling of the dose every 2 to 4 weeks up to target doses 
recommended by guidelines).
The primary outcome was the all-cause mortality according to beta-blocker use.
After discharge, events including death and re-hospitalization were recorded. The follow-up 
data were collected by the attending physician and stored in the web-based case report form 
(30 days, 3 and 6 months, 1 to 5 years annually). The outcome data for patients who had not 
been followed up have been ascertained by a telephone interview. In addition, the outcome 
data for patients lost to follow-up will be collected from the National Death Records. The 
details were previously described.12) The independent investigators monitored data monthly. 
The clinical event committee was composed of independent experts in HF who have not 
participated in patient enrolment for this study and verified all clinical events.
Statistical analysis
Descriptive statistics were calculated to summarize characteristics, treatment, and outcomes. 
Missing data were handled with MICE package. Continuous variables were expressed as the 
mean±standard deviation and compared with t-test and analysis of variance. Categorical 
data are summarized as the frequency and proportion and compared with χ2 test. Survival 
curves were constructed using Kaplan-Meier method and compared with the log-rank test. 
A propensity score for treatment with beta-blocker was estimated using variables which are 
known to be related to both the group assignments and the outcome variables; sex, age, 
height, body mass index, systolic blood pressure, smoking, admission route, hypertension, 
diabetes, pulmonary congestion, ischemic heart disease, alcohol, cancer, atrial fibrillation 
(AF), chronic obstructive lung disease, chronic kidney disease, stroke, functional class, history 
of congestive HF, sodium, potassium, hemoglobin, EF, ischemic heart disease as aggravating 
factor, amiodarone, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, 
loop diuretics, digoxin, warfarin, aspirin, statin, and heart rate difference from discharge to last 
follow up. Carvedilol, bisoprolol, metoprolol, and nebivolol were considered as ‘recommended 
beta-blocker’ and amosulalol, atenolol, betaxolol, bevantolol, celiprolol, propranolol, and 
sotalol were considered as ‘non-recommended beta-blocker.’ The propensity score matching 
(1:1) was performed by a nearest matching without replacement. Covariates valancing were 
measured by their standardized differences in means. The balance of matching was assessed 
by absolute standardized differences (the difference in percentage between the means for the 2 
groups divided by the mutual standard deviation). It is considered that pre-treatment variable 
balancing can be achieved if the absolute standardized difference of means is less than 10%. 
The Cox proportional hazards regression model was used to compare the clinical outcomes as 
beta-blocker use in the unmatched and propensity score matched cohort. For the heterogeneity 
of beta-blocker effect, subgroup analysis was performed. Statistical analyses were performed 
using R 3.3.1 (R Foundation, Vienna, Austria).15)16) R packages of survival and MatchIt were used 
to conduct the survival analysis and to construct the matched cohort, respectively. All reported 
p values are 2-sided, and p values of <0.05 were considered statistically significance.
RESULTS
Patient characteristics
Of 5,625 patients enrolled in the KorAHF registry, 2,087 patients had HFpEF: 979 received and 
1,108 did not receive beta-blockers at the discharge. After propensity score matching, there were 
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979 pairs. Baseline characteristics are shown for the unmatched and matched HFpEF cohort in 
Table 1. In the unmatched HFpEF cohort, the mean age was similar (71 years) and female were 
more often (60.5% in no beta-blocker, 55.2% in beta-blocker, p=0.016). Patients discharged 
on beta-blocker had higher body mass index, more pulmonary congestion, and received more 
angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) than 
those without beta-blocker. After matching the baseline characteristics became well balanced 
between the groups (Table 1).
Main outcomes in patients with heart failure with preserved ejection fraction
During a median follow-up duration of 807 days (interquartile range, 498–1,122 days). Main 
outcomes were summarized Figure 1 and Table 2. After adjustment for significant covariates, 
beta-blocker at discharge was associated with a lower all-cause death (hazard ratio [HR], 
0.80; 95% confidence interval [CI], 0.68–0.93). However, there was no significant difference 
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Table 1. Baseline characteristics
Variables
Unmatched cohort
p value
Propensity score matched cohort Standardized 
difference (%) p valueNo beta-blocker 
(n=1,108)
Beta-blocker 
(n=979)
No beta-blocker 
(n=979)
Beta-blocker 
(n=979)
Female (%) 670 (60.5) 540 (55.2) 0.016 570 (58.2) 540 (55.2) 7.5 0.186
Age (years) 71.6±13.5 71.2±13.4 0.496 71.7±13.3 71.2±13.4 0.8 0.490
BMI (kg/m2) 23.4±3.7 23.8±4.1 0.013 23.6±3.7 23.8±4.1 7.6 0.272
Height (cm) 157.7±9.2 158.8±9.5 0.010 158.1±9.2 158.8±9.5 6.1 0.115
SBP (mmHg) 135.5±30.8 137.3±31.1 0.190 136.7±30.8 137.3±31.1 3.4 0.717
DBP (mmHg) 77.4±18.6 78.7±18.8 0.116 77.8±18.3 78.7±18.8 4.6 0.295
Heart rate at admission (bpm) 88.7±26.7 87.8±25.3 0.428 88.8±26.6 87.8±25.3 1.9 0.368
Pulmonary congestion 846 (76.4) 796 (81.3) 0.007 780 (79.7) 796 (81.3) 8.1 0.392
Smoking 0.536 3.2 0.877
Current 132 (11.9) 127 (13.0) 121 (12.4) 127 (13.0)
Ex-smoking 194 (17.5) 183 (18.7) 179 (18.3) 183 (18.7)
Never 782 (70.6) 669 (68.3) 679 (69.4) 669 (68.3)
Alcohol 0.326 1.9 0.691
Heavy 61 (5.5) 52 (5.3) 56 (5.7) 52 (5.3)
Social 278 (25.1) 274 (28.0) 258 (26.4) 274 (28.0)
Never 769 (69.4) 653 (66.7) 665 (67.9) 653 (66.7)
Admission route 0.309 3.8 0.524
Emergency room 830 (74.9) 753 (76.9) 740 (75.6) 753 (76.9)
Out-patient clinic 278 (25.1) 226 (23.1) 239 (24.4) 226 (23.1)
HT 731 (66.0) 672 (68.6) 0.212 665 (67.9) 672 (68.6) 2.6 0.771
DM 376 (33.9) 363 (37.1) 0.146 353 (36.1) 363 (37.1) 4.3 0.673
IHD 414 (37.4) 381 (38.9) 0.494 379 (38.7) 381 (38.9) 3.0 0.963
CHF 434 (39.2) 389 (39.7) 0.827 377 (38.5) 389 (39.7) 1.7 0.610
OMI 131 (11.8) 111 (11.3) 0.782 118 (12.1) 111 (11.3) 1.0 0.673
Percutaneous coronary intervention 157 (14.2) 132 (13.5) 0.697 147 (15.0) 132 (13.5) 0.9 0.365
Coronary bypass graft 42 (3.8) 34 (3.5) 0.788 39 (4.0) 34 (3.5) 0.5 0.633
AF 349 (31.5) 336 (34.3) 0.186 311 (31.8) 336 (34.3) 4.6 0.249
COPD 136 (12.3) 119 (12.2) 0.987 114 (11.6) 119 (12.2) 0.6 0.780
CKD 147 (13.3) 125 (12.8) 0.785 118 (12.1) 125 (12.8) 1.9 0.681
Stroke 172 (15.5) 159 (16.2) 0.698 157 (16.0) 159 (16.2) 0.9 0.951
Cancer 87 (7.9) 72 (7.4) 0.730 70 (7.2) 72 (7.4) 1.5 0.931
ICD 12 (1.1) 11 (1.1) 1.000 10 (1.0) 11 (1.1) 0 1.000
CRT 4 (0.4) 1 (0.1) 0.448 3 (0.3) 1 (0.1) 0 0.617
NYHA class 0.623 1.8 0.637
II 188 (17.0) 182 (18.6) 166 (17.0) 182 (18.6)
III 410 (37.0) 357 (36.5) 366 (37.4) 357 (36.5)
IV 510 (46.0) 440 (44.9) 447 (45.7) 440 (44.9)
Sodium (mEq/L) 137.7±4.6 137.5±5.0 0.378 137.6±4.6 137.5±5.0 5.4 0.651
Potassium (mEq/L) 4.3±0.7 4.3±0.7 0.278 4.3±0.7 4.3±0.7 2.4 0.692
(continued to the next page)
in the risk of rehospitalization for HF (HR, 1.03; 95% CI, 0.85–1.27). In the propensity score 
matched population, beta-blocker at discharge was associated with a reduced risk of all-
cause death (HR, 0.78; 95% CI, 0.66–0.91), as well. The post-discharge rehospitalization 
did not differ between those with or without beta-blockers (HR, 1.03; 95% CI, 0.83–1.27). 
The sensitivity analysis using another cut-off value demonstrated the consistent results 
(Supplementary Tables 1 and 2)
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Variables
Unmatched cohort
p value
Propensity score matched cohort Standardized 
difference (%) p valueNo beta-blocker 
(n=1,108)
Beta-blocker 
(n=979)
No beta-blocker 
(n=979)
Beta-blocker 
(n=979)
Hemoglobin (g/dL) 11.9±2.3 12.0±2.3 0.230 12.0±2.2 12.0±2.3 1.7 0.616
Blood urea nitrogen (mg/dL) 25.4±16.2 24.5±14.7 0.181 24.7±15.2 24.5±14.7 0.3 0.713
Creatinine (mg/dL) 1.4±1.4 1.3±1.2 0.255 1.4±1.3 1.3±1.2 0.9 0.922
Ejection fraction (%) 53.7±9.3 53.7±9.0 0.990 53.6±9.3 53.7±9.0 0.6 0.775
Left atrium diameter (mm) 48.5±11.0 49.2±10.7 0.158 48.7±10.5 49.2±10.7 5.9 0.342
Aggravated by ischemia 256 (23.1) 220 (22.5) 0.771 234 (23.9) 220 (22.5) 0.7 0.486
ACEI or ARB 621 (56.0) 599 (61.2) 0.020 579 (59.1) 599 (61.2) 3.3 0.380
Beta-blocker before admission 193 (17.4) 148 (15.1) 0.174 172 (17.6) 148 (15.1) 2.5 0.160
Loop diuretics 702 (63.4) 677 (69.2) 0.006 657 (67.1) 677 (69.2) 4.8 0.357
Amiodarone 68 (6.1) 52 (5.3) 0.475 55 (5.6) 52 (5.3) 0 0.842
Digoxin 201 (18.1) 214 (21.9) 0.039 191 (19.5) 214 (21.9) 7.6 0.220
Warfarin 329 (29.7) 319 (32.6) 0.168 303 (30.9) 319 (32.6) 3.5 0.467
Aspirin 580 (52.3) 515 (52.6) 0.941 519 (53.0) 515 (52.6) 1.4 0.892
Statin 425 (38.4) 395 (40.3) 0.377 396 (40.4) 395 (40.3) 1.5 1.000
Spironolactone 375 (33.8) 433 (44.2) <0.001 372 (38.0) 433 (44.2) 1.3 0.006
Hemodialysis 89 (8.0) 31 (3.2) <0.001 32 (3.3) 31 (3.2) 1.2 1.000
Transfusion 278 (25.1) 213 (21.8) 0.082 230 (23.5) 213 (21.8) 0.8 0.387
Values are presented as number (%) or mean±standard deviation. Standardized difference between the means for the 2 groups divided by the mutual standard deviation.
ACEI = angiotensin converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin receptor blocker; BMI = body mass index; bpm = beat per minute; CHF = 
congestive heart failure; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary; disease; CRT = cardiac resynchronization therapy; DBP = diastolic blood 
pressure; DM = diabetes mellitus; HT = hypertension; ICD = implantable cardioverter-defibrillator; IHD = ischemic heart disease; NYHA = New York Heart Association; OMI 
= old myocardial infarction.
Table 1. (Continued) Baseline characteristics
Table 2. Main outcomes
Outcomes Cox proportional hazards model Propensity score matched
HR 95% CI p value HR 95% CI p value
Death 0.80 0.68–0.93 0.003 0.78 0.66–0.91 0.002
Rehospitalization 1.03 0.85–1.27 0.740 1.03 0.83–1.27 0.814
CI = confidence interval; HR = hazard ratio.
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Figure 1. Kaplan-Meier curves for all-cause death in the matched cohorts among patients with heart failure with 
preserved ejection fraction.
Subgroup analysis
The reduction of all-cause death associated with beta-blocker was consistent with the 
subgroups with the exception of AF and heart rate reduction during follow up period (Figure 2). 
In patients with AF, beta-blocker at discharge was significantly associated with the reduction of 
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Variable HR 95% CI p for interaction
Age (years) 0.67
≥78 (n=1,259) 0.72 (0.58–0.90)
<78 (n=699) 0.80 (0.64–1.00)
Sex 0.68
Male (n=848) 0.78 (0.62–0.98)
Female (n=1,110) 0.73 (0.59–0.90)
NYHA 0.77
II (n=348) 0.77 (0.50–1.20)
III (n=723) 0.71 (0.55–0.92)
IV (n=887) 0.79 (0.63–0.98)
BMI (kg/m2) 0.73
≥21.4 (n=527) 0.76 (0.59–0.99)
<21.4 (n=1,431) 0.74 (0.61–0.89)
EF (%) 0.53
≥55 (n=1,064) 0.71 (0.58–0.88)
<55 (n=894) 0.81 (0.64–1.03)
DM 0.11
Yes (n=716) 0.67 (0.52–0.85)
No (n=1,242) 0.82 (0.67–1.00)
HT 0.26
Yes (n=1,337) 0.72 (0.60–0.87)
No (n=621) 0.84 (0.63–1.13)
IHD 0.19
Yes (n=760) 0.66 (0.51–0.84)
No (n=1,198) 0.83 (0.68–1.01)
AF 0.004
Yes (n=647) 0.57 (0.44–0.73)
No (n=1,311) 0.88 (0.72–1.07)
COPD 0.63
Yes (n=233) 0.68 (0.46–1.02)
No (n=1,725) 0.76 (0.65–0.90)
CKD 0.42
Yes (n=243) 0.67 (0.46–0.96)
No (n=1,715) 0.77 (0.64–0.91)
ACEI/ARB 0.32
Yes (n=1,178) 0.82 (0.67–1.01)
No (n=780) 0.68 (0.54–0.86)
Digoxin 0.57
Yes (n=405) 0.71 (0.51–0.98)
No (n=1,553) 0.76 (0.64–0.91)
HR reduction 0.047
1st (n=637) 0.92 (0.71–1.19)
2nd (n=676) 0.83 (0.64–1.10)
3rd (n=645) 0.63 (0.47–0.85)
Favor no beta blockerFavor beta blocker
1 20.5
Figure 2. Interactions and HRs for all-cause death in the matched cohorts among patients with heart failure with 
preserved ejection fraction. 
ACEI = angiotensin converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin receptor blocker; BMI = body 
mass index; CI = confidence interval; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; 
DM = diabetes mellitus; EF = ejection fraction; HR = hazard ratio; HT = hypertension; IHD = ischemic heart 
disease; NYHA = New York Heart Association.
all-cause mortality (HR, 0.57; 95% CI, 0.44–0.73), but it was not in patients without AF (HR, 
0.88; 95% CI, 0.72–1.07). As more heart reduction were achieved during follow period, beta-
blocker was significantly associated with lower all-cause mortality (3rd tertile, 16.0±10.4 per 
minutes reduction, HR, 0.63; 95% CI, 0.47–0.85).
Pattern of beta-blocker use and outcomes in the unmatched cohort
A broad distribution of beta-blocker prescription was observed in this registry (Figure 3). 
A 39.4% of patients in the unmatched HFpEF cohort had history of congestive HF (Table 1) 
and 16.3% of patients had already received beta-blocker before enrollment. Among patients 
discharged on beta-blocker at discharge, 62.2% of patients (n=609) received beta-blocker 
consistently during follow-up period but 37.8% of patients (n=370) did irregularly. Given beta-
blockers were mostly recommended one (97.2%). Among patients who received beta-blocker 
regularly, only 18.6% of patients received 50% or more target dose. The prescription of 
regular and recommended beta-blocker was associated with all-cause mortality respectively. 
After using Cox proportional hazards models, the HR for all-cause mortality was 0.77 (95% 
CI, 0.64–0.93) lower for patients with regular beta-blocker and 0.62 (95% CI, 0.47–0.82) 
lower for patients with recommended beta-blocker respectively. However, the dose of beta-
blocker was not associated with all-cause mortality (HR, 0.84; 95% CI, 0.60–1.18).
DISCUSSION
The effect of beta-blocker in patients with HFpEF is controversial. In our study we could 
show that, beta-blocker at discharge was associated with reduced all-cause death, but not 
with rehospitalization in patients with HFpEF after adjustment of significant covariates and 
propensity-score matching. Our findings were also strengthened by additional analysis for 
the pattern and outcomes of beta-blocker prescription after discharge.
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Beta blocker before admission
(n=341, 163%)
Beta blocker at discharge
(n=979, 46.9%)
No beta blocker at discharge
(n=1,108, 53.1%)
Beta blocker, recommended
(n=487, 97.2%)
During follow-up
During admission
Before enrollment
Beta blocker, not recommended
(n=14, 2.8%)
Beta blocker, regular
(n=609, 29.2%)
Beta blocker, irregular
(n=1,017, 48.7%)
Beta blocker, never
(n=461, 22.1%)
Beta blocker, ≥50%
(n=90, 18.6%)
Beta blocker, 25–50%
(n=161, 33%)
Beta blocker, 12.5–25%
(n=154, 33%)
Beta blocker, <15.5%
(n=60, 15%)
609 307 647 461
Figure 3. Pattern of beta-blocker prescriptions.
Since Bavishi et al.17) reported firstly that propranolol decreased mortality in patients with 
HFpEF and old myocardial infarction, the results of subsequent studies were controversial. 
J-DHF study was the first and only prospective randomized trial to investigate the effect 
of carvedilol in patients with HFpEF (Table 3). Contrast to our results, J-DHF study failed 
to show the reduction of all-cause death as well as the primary outcome, a composite of 
cardiovascular death and unexplained hospitalization for HF. This difference may have 
several explanations. In J-DHF study, both stable chronic HF patients as well as acute HF 
patients were enrolled, whereas our study population included only hospitalized acute HF 
patients. So, beta-blocker initiation and titration could be considered more safely in our 
study. Furthermore, in J-DHF study the expected number of events was not achieved due to 
poor enrollment and had high loss to follow-up rate.9) All-cause death occurred in just 39 
patients (15.9%) among J-DHF study, but in 702 patients (33.6%) in our cohort. In addition, 
patients with New York Heart Association (NYHA) class II were 72.2%, which was too high 
compared usual HF cohort as well as our cohort, so the results should be interpreted with 
caution. Similar with our results, Lund et al.11) have demonstrated that use of beta-blocker 
was associated with lower all-cause death but not with HF rehospitalization (Table 3). 
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Table 3. Comparison of previous studies
Variables
Present cohort (matched) J-DHF (randomly assigned) Sweden registry (matched)
No beta-blocker 
(n=979)
Beta-blocker  
(n=979)
No carvedilol  
(n=125)
Carvedilol  
(n=120)
No beta-blocker 
(n=1,108)
Beta-blocker  
(n=979)
Enrollment EF ≥40% (2011–2014) EF >40% (2004–2009) EF ≥40% (2005–2012)
Physician Cardiologist at tertiary hospital Cardiologist A half of patients cared by non-cardiologist
Race Asian (Korean) Asian (Japanese) Caucasian (Swedish)
Follow duration (days) 807 1,168 755
Female (%) 570 (58.2) 540 (55.2) 52 (41.6) 51 (42.5) 1,256 (46) 2,518 (46)
Age (years) 71.7±13.3 71.2±13.4 71±11 73±10 78 (11) 78 (11)
BMI (kg/m2) 23.6±3.7 23.8±4.1 24.1±4.1 24.2±4.4
SBP (mmHg) 136.7±30.8 137.3±31.1 133±21 134±21 132 (21) 132 (22)
HR at admission (bpm) 88.8±26.6 87.8±25.3 74±13 72±11 73 (15) 74 (15)
Pulmonary congestion 780 (79.7) 796 (81.3) N/A N/A 748 (40) 1,518 (41)
Inpatients All (via emergency room, 75%) N/A N/A 1,713 (62) 3,534 (64)
HT 665 (67.9) 672 (68.6) 101 (80.8) 96 (80.0) 1,533 (56) 3,164 (58)
DM 353 (36.1) 363 (37.1) 42 (33.6) 33 (27.5) 666 (24) 1,353 (25)
CHF 377 (38.5) 389 (39.7) 75 (60.0) 72 (60.0) 1,437 (53) 2,870 (53)
OMI 118 (12.1) 111 (11.3) 787 (29) 1,755 (32)
AF 311 (31.8) 336 (34.3) 57 (45.6) 61 (50.8) 1,478 (54) 2,839 (52)
Stroke 157 (16.0) 159 (16.2) 16 (12.8) 14 (11.7) 537 (20) 1,020 (19)
Cancer 70 (7.2) 72 (7.4) N/A N/A N/A N/A
ICD 10 (1.0) 11 (1.1) N/A N/A N/A N/A
CRT 3 (0.3) 1 (0.1) N/A N/A N/A N/A
NYHA class
II 166 (17.0) 182 (18.6) 94 (75.2) 83 (69.1) 775 (47) 1,618 (46)
III 366 (37.4) 357 (36.5) 6 (4.8) 13 (10.8) 570 (35) 1,098 (31)
IV 447 (45.7) 440 (44.9) 2 (1.6) 2 (1.7) 54 (3) 126 (4)
Ejection fraction (%) 53.6±9.3 53.7±9.0 63+11 62+10 N/A N/A
Aggravated by ischemia 234 (23.9) 220 (22.5) 15 (12) 21 (17.5) N/A N/A
ACEI or ARB 579 (59.1) 599 (61.2) 88 (70.4) 85 (70.8) 716 (26) 1,279 (23)
Digoxin 191 (19.5) 214 (21.9) 27 (21.6) 23 (19.2) 379 (14) 874 (16)
Outcomes
All-cause death 0.80 (0.69–0.94) 0.99 (0.53–1.87) 0.93 (0.86–0.996)
Rehospitalization 1.08 (0.87–1.33) 0.90 (0.54–1.49) 0.98 (0.92–1.04)
Values are presented as number (%) or mean±standard deviation.
ACEI = angiotensin converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin receptor blocker; BMI = body mass index; bpm = beat per minute; CHF 
= congestive heart failure; CRT = cardiac resynchronization therapy; DBP = diastolic blood pressure; DM = diabetes mellitus; HR = hazard ratio; HT = hypertension; 
ICD = implantable cardioverter-defibrillator; J-DHF = Japanese Diastolic Heart Failure; NYHA = New York Heart Association; OMI = old myocardial infarction;  
SBP = systolic blood pressure.
However, the risk reduction of beta-blocker was of smaller magnitude compared our results. 
Geographic and ethnic differences in the response of beta-blocker have been suggested.18-20) 
A higher prevalence of central obesity and insulin resistance in Korean, are likely to have a 
higher sympathetic activity.21) It may benefit from the use of a beta-blocker for the treatment 
of hypertension and HF.19) In prEserveD left ventricular ejectIon fraction chronic heart Failure 
with ivabradine studY (EDIFY) trial, further heart rate reduction by ivabradine was not 
associated with improved surrogate outcomes.22) The discrepancy with our results could be 
explained. First, the patients in EDIFY trial had chronic HF and stable heart rate in baseline 
compared with our patients. In our registry, heart rate at discharge were variable (38–160 
bpm) and some patients were discharged with tachycardia (>90 bpm, 15% of HFpEF cohort). 
It means that tachycardia could be significant cause of HF and heart rate reduction would be 
beneficial. Second, majority of patients in EDIFY already had beta-blocker and the goal of 
EDIFY was the additional benefit of ivabradine. There is no patient who had ivabradine in our 
HFpEF cohort. European investigators recently reported that beta-blocker was not effective 
in reducing mortality in patients with HFpEF (≥50% of EF).23) However, in this meta-analysis, 
the number of patients with preserved EF (≥40%) was only half of our cohort and patients 
who had more than 50% of EF was only 314 (2.2% of whole patients). Duration of follow-
up was much shorter (1.3 year) than that of our cohort. As Cleland et al.23) acknowledged at 
the paper, there were too few patients and events to draw any conclusions in patients with 
more preserved LVEF. Second, all of our patients were diagnosed as acute HF. The baseline 
characteristics including ethnicity was different. Ischemia as etiology was about 90% in 
Cleland's paper but only 23% in our patients. Female was majority of our patients.
We identified AF as subgroup was superior to beta-blocker treatment with regard to efficacy. 
A sophisticated meta-analysis reported that beta-blocker led to a significant reduction in 
all-cause death in patients with sinus rhythm, but not in patients with AF.24) However, as the 
author acknowledged, patient with HFpEF accounted for only 1.8% of the pooled population. 
Although the interaction was not significant (p for interaction=0.10) in the Swedish HF 
registry, subgroup with AF had also more benefit from beta-blocker compared patients with 
sinus rhythm. More convincing comment requires the accumulation of large evidence for the 
efficacy of beta-blocker according to the rhythms status in patients with HFpEF.
There are several limitations. First, rehospitalization was collected by medical record review or 
telephone interview. So, it would be not easy to adjudicate and missed in case of admission to 
other hospital. Less duration of follow up for rehospitalization would be affected compared with 
that for death which were collected from the National Death Records. Second, noncardiovascular 
comorbidity is more common in HFpEF. Third, the side effects of beta-blocker, that are 
bradycardia, hypotension, and syncope, would offset the effective of beta-blocker.
In conclusion, in Korean patients with HFpEF, use of beta-blockers is associated with 
reduced all-cause death but not with reduced rehospitalization.
SUPPLEMENTARY MATERIALS
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